Buscar

Estamos realizando la búsqueda. Por favor, espere...

 Detalle_Publicacion

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

Abstract: Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) is the first prospective study of real-life standard of care (SOC) in triple-class exposed (received at least a PI, IMiD, and anti-CD38 mAb) patients with relapsed/refractory MM (RRMM). Patients (N = 248; ECOG performance status of 0?1, ?3 prior lines of therapy or double refractory to a PI and IMiD) were treated with median 4.0 (range, 1?20) cycles of SOC therapy. Overall response rate was 29.8% (95% CI: 24.2?36.0). Median progression-free survival (PFS) and median overall survival (OS) were 4.6 (95% CI: 3.9?5.6) and 12.4 months (95% CI: 10.3?NE). Treatment-emergent adverse events (TEAEs) were reported in 83.5% of patients (52.8% grade 3/4). Altogether, 107 deaths occurred, due to progressive disease (n = 74), TEAEs (n = 19), and other reasons (n = 14). The 92 varied regimens utilized demonstrate a lack of clear SOC for heavily pretreated, triple-class exposed patients with RRMM in real-world practice and result in poor outcomes. This supports a need for new treatments with novel mechanisms of action.

Otras publicaciones de la misma revista o congreso con autores/as de la Universidad de Cantabria

 Autoría: Maria-Victoria Mateos, Katja Weisel, Valerio De Stefano , Hartmut Goldschmidt , Michel Delforge , Mohamad Mohty , Michele Cavo , Ravi Vij , Joanne Lindsey-Hill , Dominik Dytfeld , Emanuele Angelucci , Aurore Perrot , Reuben Benjamin , Niels W. C. J. van de Donk , Enrique M. Ocio , Christof Scheid , Francesca Gay , Wilfried Roeloffzen, Paula Rodriguez-Otero, Annemiek Broijl, Anna Potamianou, Caline Sakabedoyan, Maria Semerjian, Sofia Keim, Vadim Strulev, Jordan M. Schecter, Martin Vogel, Robert Wapenaar, Tonia Nesheiwat, Jesus San-Miguel , Pieter Sonneveld , Hermann Einsele and Philippe Moreau

 Fuente: Leukemia, 2022, 36(5),1371-1376

Editorial: Nature Publishing Group

 Año de publicación: 2022

Nº de páginas: 6

Tipo de publicación: Artículo de Revista

 DOI: 10.1038/s41375-022-01531-2

ISSN: 0887-6924,1476-5551

Url de la publicación: https://doi.org/10.1038/s41375-022-01531-2

Autoría

MATEOS, MARÍA VICTORIA

WEISEL, KATJA

DE STEFANO, VALERIO

GOLDSCHMIDT, HARTMUT

DELFORGE, MICHEL

MOHTY, MOHAMAD

CAVO, MICHELE

VIJ, RAVI

LINDSEY-HILL, JOANNE

DYTFELD, DOMINIK

ANGELUCCI, EMANUELE

PERROT, AURORE

BENJAMIN, REUBEN

VAN DE DONK, NIELS W. C.

GAY, FRANCESCA

ROELOFFZEN, WILFRIED

RODRIGUEZ OTERO, PAULA

BROIJL, ANNEMIEK